Advancing Breast Cancer Treatment with Elacestrant

SABCS 2024

Breast Cancer

Updates on ADCs in treatment of advanced breast cancer

Breast Cancer

Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting

Int J Cancer

Liu B, Song Y, Xu Y, Sun Q, Zhou Y, Lin Y

doi: 10.1002/ijc.35140

Breast Cancer

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

J Clin Oncol

Shah M, Lingam H, Gao X, Gittleman H, Fiero MH, Krol D, Biel N, Ricks TK, Fu W, Hamed S, Li F, Sun JJ, Fan J, Schuck R, Grimstein M, Tang L, Kalavar S, Abukhdeir A, Pathak A, Ghosh S, Bulatao I, Tilley A, Pierce WF, Mixter BD, Tang S, Pazdur R, Kluetz P, Amiri-Kordestani L

doi: 10.1200/JCO.23.02112

Breast Cancer

Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study

Eur J Cancer

Tolosa P, Pascual T, Martínez-Saez O, Hernando C, Servitja S, Fernández Abad M, Brasó-Maristany F, Sanfeliu E, Benitez Fuentes JD, Lema L, Ruano Y, García-Fructuoso I, Parrilla L, Rodríguez A, Roncero AM, Cobos MÁ, Sánchez-Bayona R, Alva M, Madariaga A, Villacampa G, Canes J, Salvador F, Sánchez-Belmonte A, Malumbres M, Prat A, Ciruelos E

doi: 10.1016/j.ejca.2024.115219

Gastrointestinal Cancer

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial

healthbook TIMES Onco Hema.

Fritsch R

doi: 10.36000/HBT.OH.2024.21.157

ESMO 2024

Breast Cancer

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

Breast Cancer

Second Primary Breast Cancer in Young Breast Cancer Survivors

JAMA Oncol

Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Warner E, Come SE, Zheng Y, Kirkner GJ, Snow C, Winer EP, Partridge AH

doi: 10.1001/jamaoncol.2024.0286

SABCS 2024

Breast Cancer

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

SABCS 2024

Breast Cancer

Related content

Updates on ADCs in treatment of advanced breast cancer

Optimizing treatment sequence for inoperable locally advanced breast cancer: Long-term outcomes of surgery first versus neoadjuvant chemotherapy in a real-world setting

US Food and Drug Administration Approval Summary: Elacestrant for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study

Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer Treatment: Insights from the TOPAZ-1 Trial

ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria

Second Primary Breast Cancer in Young Breast Cancer Survivors

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

SERENA-1: Camizestrant plus ribociclib show encouraging clinical activity in women with ER-positive, HER2-negative advanced breast cancer